Skip to main content
SpringerLink
Log in

Nelfinavir

  • Adis New Drug Profile
  • Published:
Drugs Aims and scope Submit manuscript

Summary

  • ▴ Nelfinavir is a protease inhibitor which shows good inhibitory activity against HIV-1. The pattern of HIV-1 resistance to nelfinavir is different from that seen with other protease inhibitors.

  • ▴ In healthy male volunteers, administration of single 400 and 800mg doses of nelfinavir with food resulted in area under the plasma concentration-time curve values that were 27 to 50% higher than those achieved in fasted volunteers who received the same doses of the drug.

  • ▴ Reductions in plasma HIV RNA to below detectable levels (detection limit 500 copies/ml) were achieved in some patients (number not reported) after 28 days’ treatment with nelfinavir 500, 600 or 750mg twice daily, or 500, 750 or 1000mg 3 times daily.

  • ▴ Combination therapy with nelfinavir and stavudine produced greater reductions in plasma HIV RNA levels than stavudine monotherapy in patients who had not previously received stavudine treatment; mean increases in CD4+ cell counts were also greater in the combination treatment group than in monotherapy recipients.

  • ▴ Plasma HIV RNA decreased to below detectable levels in 11 of 12 patients with early onset HIV infection who received a triple regimen of nelfinavir, zidovudine and lamivudine for 16 weeks.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Shetty BV, Kosa MB, Khalil DA, et al. Preclinical pharmacokinetics and distribution to tissue of AG1343, an inhibitor of human immunodeficiency virus type 1 protease. Antimicrob Agents Chemother 1996 Jan; 40: 110–4

    PubMed  CAS  Google Scholar 

  2. Kaplan AH, Zack JA, Knigge M, et al. Partial inhibition of the human immunodeficiency virus type 1 protease results in aberrant virus assembly and the formation of noninfectious particles. J Virol 1993 (67): 4050–5

  3. Peng C, Ho BK, Chang TW, et al. Role of human immunodeficiency virus type 1-specific protease in core protein maturation and viral infectivity. J Virol 1989; 63: 2550–6

    PubMed  CAS  Google Scholar 

  4. Shetty B, Kaldor S, Kalish V, et al. AG1343, an orally bioavailable non-peptidic HIV-1 protease inhibitor [abstract]. 10th International Conference on AIDS; 1994 Aug 7–12; Yokohama, 7

  5. Patick AK, Mo H, Markowitz M, et al. In vitro antiviral and resistance studies of AG1343, an orally bioavailable inhibitor of HIV-1 protease [abstract]. 2nd National Conference on Human Retroviruses and Related Infections; 1995 Jan 29–Feb 2; Washington, DC, 88

  6. Patick AK, Mo H, Markowitz M, et al. Antiviral and resistance studies of AG1343, an orally bioavailable inhibitor of human immunodeficiency virus protease. Antimicrob Agents Chemother 1996; 40: 292–7

    PubMed  CAS  Google Scholar 

  7. Webber S, Khalil D, Kosa M, et al. Preclinical toxicokinetic studies with AG1343, an orally bioavailable HIV-1 protease inhibitor [abstract]. 2nd National Conference on Retroviruses and Related Infections; 1995 Jan 29–Feb 2, 71

  8. Agouron Pharmaceuticals Inc. Nelfinavir mesylate prescribing information. La Jolla (CA), 1997

  9. Moyle G, Gazzard B. Current knowledge and future prospects for the use of HIV protease inhibitors. Drugs 1996 May; 51: 701–12

    Article  PubMed  CAS  Google Scholar 

  10. Patick AK, Duran M, Cao Y, et al. HIV-1 variants isolated from patients treated with the protease inhibitor, nelfinavir are not cross-resistant to other protease inhibitors [abstract]. AIDS 1996; 10 Suppl. 2: OP9.2

    Google Scholar 

  11. Patick AK, Duran M, Cao Y, et al. Genotypic analysis of HIV-1 variants isolated from patients treated with the protease inhibitor nelfinavir, alone or in combination with d4T or AZT and 3TC [abstract]. 4th Conference on Retroviruses and Opportunistic Infections; 1997 Jan 22–26; Washington, DC, no. 10

  12. Anon. Patterns of resistance to protease inhibitors. Inpharma 1996 Aug 3; 1048: 11

  13. Markowitz M, Conant M, Hurley A, et al. Phase I/II dose range-finding study of the HIV protease inhibitor AG1343 [abstract]. 35th Int Conf Antimicrob Agents Chemother. 1995 Sep 17–20 Program Addendum: 8

  14. Quart BD, Chapman SK, Peterkin J, et al. Phase I safety, tolerance, pharmacokinetics and food effect studies of AG1343 — a novel HIV protease inhibitor [abstract]. 2nd National Conference on Human Retroviruses and Related Infections; 1995 Jan 29–Feb 2: 167

  15. Youle M, Moyle G, Chapman S, et al. Phase I/II study of AG1343, a novel HIV protease inhibitor [abstract]. Can J Infect Dis 1995 Jul; 6 Suppl. C: 369C

    Google Scholar 

  16. Moyle G, Youle M, Chapman S, et al. A phase II dose escalation study of the Agouron protease inhibitor AG 1343 [abstract]. 35th Int Conf Antimicrob Agents Chemother. 1995 Sep 17–20 Program Addendum: 8

  17. Webber S, Shetty B, Wu E, et al. In vitro and in vivo metabolism and cytochrome P450 induction studies with the HIV-1 protease inhibitor, Viracept (Rm) (AG1343) [abstract]. 3rd Conference on Retroviruses and Opportunistic Infections; 1996 Jan 28–Feb 1: Washington, DC, 79

  18. Kerr B, Lee C, Yuen G, et al. Overview of in-vitro and in-vivo drug interaction studies of nelfinavir mesylate (NFV), a new HIV-1 protease inhibitor [abstract]. 4th Conference on Retroviruses and Opportunistic Infections; 1997 Jan 22–26; Washington, DC, no. 373

  19. Kempf D, Marsh K, Denissen J, et al. Coadministration with ritonavir enhances the plasma levels of HIV protease inhibitors by inhibition of cytochrome P450 [abstract]. 3rd Conference on Retroviruses and Opportunistic Infections; 1996 Jan 28–Feb 1, Washington, DC, 79

  20. Pedneault L, Elion R, Adler M, et al. Stavudine (d4T), didanosine (ddI), and nelfinavir combination therapy in HIV-infected subjects: antiviral effect and safety in an ongoing pilot study [abstract]. 4th Conference on Retroviruses and Opportunistic Infections. 1997 Jan 22–26; Washington, DC, no. 241

  21. Krogstad P, Kerr B, Anderson R, et al. Phase I study of the HIV-protease inhibitor nelfinavir mesylate (NFV) in HIV+ children [abstract]. 4th Conference on Retroviruses and Opportunistic Infections. 1997 Jan 22–26; Washington, DC, no. 721

  22. Conant M, Markowitz M, Hurley A, et al. A randomized phase II dose range-finding study of the HIV protease inhibitor Viracept™ as monotherapy in HIV positive patients [abstract]. 11th International Conference on AIDS; 1996 Jul 7–12; Vancouver, 286–7

  23. Gathe JJ, Burkhardt B, Hawley P, et al. A randomized phase II study of Viracept™, a novel HIV protease inhibitor, used in combination with stavudine vs. stavudine alone [abstract]. 11th International Conference on AIDS; 1996 Jul 7–12; Vancouver, 25

  24. Clinical trials update. Scrip 1996 Jun 18 (2138): 20

  25. Henry K, Lamarca A, Myers R, et al. The safety of VIRACEPT® (nelfinavir mesylate) in pivotal phase II/III double-blind randomized controlled trials as monotherapy and in combination with d4T or AZT/3TC [Poster]. 4th Conference on Retroviruses and Opportunistic Infections; 1997 Jan 22–26; Washington, DC

  26. Markowitz M, Winslow D, Cao Y, et al. Triple therapy with nelfinavir (Viracept®) in combination with AZT and 3TC in 12 antiviral-naive subjects chronically infected with HIV-1 [abstract]. Tenth International Conference on Antiviral Research; 1997 Apr 6–11; Atlanta

  27. Connett S. First dual protease inhibitor combination shows promise. Bioworld Today 1996 Jul 11; 7: 1 & 3

    Google Scholar 

  28. Prescott L. Redefining the approach to treating HIV infection. Inpharma 1996 Aug 30; 1052: 13–4

    Google Scholar 

  29. Henry K, Lamarca A, Myers R, et al. The safety of Viracept™ (nelfinavir mesylate, NFV) in pivotal phase II/III double-blind randomized controlled trials as monotherapy and in combination with either d4T or AZT/3TC [abstract]. 4th Conference on Retroviruses and Opportunistic Infections; 1997 Jan 22–26; Washington, DC

  30. Deeks SG, Smith M, Holodniy M, et al. HIV-1 protease inhibitors: a review for clinicians. JAMA 1997; 277(2): 145–153

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Adis International Limited, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, Auckland 10, New Zealand

    Caroline M. Perry & Paul Benfield

Authors
  1. Caroline M. Perry
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Paul Benfield
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Caroline M. Perry.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Perry, C.M., Benfield, P. Nelfinavir. Drugs 54, 81–87 (1997). https://doi.org/10.2165/00003495-199754010-00007

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-199754010-00007

Keywords

Search

Navigation